Clinical Associate Prof Tai Wai Meng David was giving his presentation on Implications of Immunotherapy Data in Unresectable HCC. There were three highlights from his session:
Clinical Associate Prof Tai Wai Meng David was giving his presentation on Implications of Immunotherapy Data in Unresectable HCC. There were three highlights from his session:
+ As a perspective, comparison between HCC treatment studies (Imbrave 150, Himalaya, and Cosmic 312) atezolizumab + bevacizumab provide the longest overall survival as well as highest overall response rate
+ Combination Atezolizumab and Bevacizumab – favored option if patient fulfills eligibility criteria.
+TKI favored option in second line after progression on first line IO therapy.
